CagriSema: Semaglutide + Cagrilintide Combination and What Phase III Results Mean

CagriSema is Novo Nordisk's fixed-ratio combination of two distinct weight-loss mechanisms: semaglutide, the GLP-1 receptor agonist already proven in Ozempic and Wegovy, and cagrilintide, a long-acting amylin analog. The pairing is deliberate — semaglutide and amylin work through complementary, largely non-overlapping pathways, and combining them produces weight loss that appears greater than either agent alone.

The Phase III REDEFINE program published its first significant results in 2024–2025, and the combination has since become one of the most closely watched assets in metabolic medicine.

What Is Cagrilintide?

Amylin is a hormone co-secreted with insulin from pancreatic beta cells in response to meals. Its physiological role is to complement insulin: amylin slows gastric emptying, suppresses glucagon, and sends satiety signals to the hypothalamus through its own receptor pathway — distinct from the GLP-1 receptor.

Pramlintide (Symlin) was the first approved amylin analog, used as an injectable adjunct to insulin in type 1 and type 2 diabetes. Its major limitation was a short half-life requiring dosing with each meal.

Cagrilintide solves this problem. It is an engineered long-acting amylin analog with a half-life suitable for once-weekly dosing — matching the semaglutide injection schedule. This pharmacokinetic alignment made the fixed-ratio combination practical.

Why Combine GLP-1 and Amylin?

The rationale is receptor complementarity. GLP-1 receptors are concentrated in the brain, pancreas, gut, and cardiovascular system. Amylin receptors are distinct and located in overlapping but different regions, particularly the area postrema and hypothalamus. Activating both pathways:

• Produces additive satiety signaling without requiring higher doses of either component
• Affects gastric emptying through two independent mechanisms
• May allow lower doses of semaglutide while maintaining efficacy — potentially reducing GI side effects

In early Phase I and II studies, cagrilintide added meaningfully to semaglutide's weight loss effect. The 2023 Phase IIb trial showed mean weight loss of approximately 15.6% at 32 weeks for the combination versus 5.1% for cagrilintide alone and 8.0% for semaglutide alone at the same doses.

REDEFINE Phase III Trial Results

The REDEFINE program is a series of Phase III trials evaluating CagriSema across different populations. The landmark REDEFINE 1 trial enrolled approximately 3,400 adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with comorbidities.

Participants received CagriSema 2.4 mg/2.4 mg (semaglutide/cagrilintide) once weekly via subcutaneous injection over 68 weeks. Results:

• Mean weight reduction: 22.7% from baseline
• Placebo-adjusted reduction: approximately 20%
• Proportion achieving ≥20% weight loss: more than 40% of participants
• Proportion achieving ≥25% weight loss: approximately 20%

These results are competitive with tirzepatide and numerically ahead of semaglutide monotherapy, positioning CagriSema as a leading candidate for the next tier of approved weight-loss medications.

REDEFINE 2 evaluated the combination specifically in people with type 2 diabetes, where GLP-1 agents typically show somewhat attenuated weight loss. Results in this population showed approximately 15% mean weight reduction, still a substantial improvement over existing options.

CagriSema vs. Tirzepatide vs. Semaglutide

| Agent | Mechanism | Phase III Weight Loss | |---|---|---| | Semaglutide 2.4mg | GLP-1 | ~15% | | Tirzepatide 15mg | GLP-1/GIP | ~22% | | CagriSema 2.4mg/2.4mg | GLP-1/Amylin | ~22.7% |

CagriSema and tirzepatide produce similar magnitudes of weight loss through entirely different secondary mechanisms — GIP agonism versus amylin agonism. This matters clinically because patients who do not respond optimally to one mechanism may respond better to the other, and it opens the door to eventual combination or sequencing strategies.

Side Effect Profile

The side effect profile of CagriSema is shaped by both components:

From semaglutide (GLP-1 component):

• Nausea, vomiting, diarrhea — most common during dose escalation
• Constipation at steady state
• Rare cases of pancreatitis (as with all GLP-1 agents)

From cagrilintide (amylin component):

• Nausea and vomiting — amylin analogs independently cause GI effects
• Injection site reactions reported at somewhat higher rates than semaglutide alone

The combination carries a higher GI burden than semaglutide monotherapy, particularly during the dose escalation period. REDEFINE 1 showed discontinuation rates of approximately 16% in the active arm, higher than typical semaglutide trials, largely driven by GI side effects.

The dose escalation schedule for CagriSema is deliberately slow — gradual titration over many months before reaching the maintenance dose — to improve tolerability.

Development Timeline

CagriSema completed Phase III recruitment and has reported top-line data from REDEFINE 1. Novo Nordisk is expected to submit regulatory applications in the United States and European Union in 2025–2026, with potential approval in 2026 pending FDA review. The compound does not yet have a brand name for its weight management indication.

CagriSema is also being evaluated for cardiovascular outcomes in a dedicated SELECT-style trial, recognizing that the metabolic benefit needs cardiometabolic endpoint data to secure the broadest label.

Practical Implications for Patients

If approved, CagriSema will likely be positioned for patients seeking greater weight loss than semaglutide achieves, particularly those who have not reached weight goals on GLP-1 monotherapy. The combination's distinct mechanism from tirzepatide means it could serve as:

• A first-line choice for patients who do not tolerate GIP agonism
• A second-line option after inadequate response to existing agents
• A treatment option in populations with type 2 diabetes where amylin deficiency is particularly relevant

For those exploring peptides available now, see our guides on Mod GRF 1-29 and the peptide stacking guide for context on how combination peptide strategies work.

Frequently Asked Questions

Q: What makes CagriSema different from Ozempic or Wegovy? CagriSema adds cagrilintide, a long-acting amylin analog, to semaglutide. Amylin acts through different receptors than GLP-1, providing complementary satiety signals and enabling greater weight loss than semaglutide alone.

Q: Is CagriSema approved yet? As of early 2026, CagriSema is not approved in any country. Phase III data has been published and regulatory submissions are anticipated in 2025–2026.

Q: How does CagriSema compare to tirzepatide? Both produce approximately 22% weight loss in Phase III trials but through different mechanisms — tirzepatide uses GIP agonism, CagriSema uses amylin agonism. Clinical profiles differ in ways that may matter for individual patients.

Q: Does cagrilintide cause nausea? Yes. Amylin analogs independently cause nausea. Combined with semaglutide, CagriSema carries a higher GI side effect burden than semaglutide alone, particularly during dose escalation.

Q: What is the injection schedule? CagriSema is administered once weekly via subcutaneous injection, matching the semaglutide dosing schedule that patients are already familiar with.